BCMA targeting bispecific antibodies in relapsed/refractory MM
| Variable . | Teclistamab5,6 . | Elranatamab7 . | Elranatamab8 . | Linvoseltamab10 . | Alnuctamab11,12 . | ABBV-38313,15 . | HPN-217-300114 . |
|---|---|---|---|---|---|---|---|
| Patients, n | 165 | 55 | 123 | 117 | 73 | 124 | 97 |
| Dosing schedule | Weekly/q2w SC | Weekly/q2w SC | Weekly/q2w IV | Weekly/q2w or q4w IV | Weekly/q2-4w IV/SC | Q3w-q4w IV | Weekly/q2w |
| Median prior LOT | 5 | 6 | 5 | 5 | 4 | 5 | 6 |
| ISS III/ ↑↑ PC, % | 12.3/11.2 | 20/— | 15.4/21.1 | 18.8/22.2 | 16/— | 31/— | 38/— |
| HR/EMD, % | 25.7/17 | 29.1/30.9 | 25.2/31.7 | 35.9/13.7 | 26/21 | 18/— | 19/10 |
| TCR, % | 77.6 | 90.9∗ | 100 | 73.5 | 63 | 82 | 78 |
| ORR/≧ CR, % at RP2D | 63/45.5 1500 μg/kg SC | 64/38.2 76 mg SC | 61/35 76 mg SC | 71/30 200 mg IV | 69/43 30 mg SC | 57/28 40-60 mg IV | 63/21 12 mg |
| Median DOR | 21.6 mo | 17.1 mo | 71.5% at 15 mo | — | — | 72.2% at 12 mo† | 20.5 mo |
| Median PFS | 11.3 mo ≦ 3 LOT 18.1 mo | 11.8 mo | 50.9% at 15 mo | 72.7% at 6 mo | 53% at 12 mo | 10.4 mo 57.9% at 12 mo† | — |
| Median OS | 21.9 mo | 21.2 mo | 56.7% at 15 mo | — | — | — | — |
| Hematological AE (any grade/G3-4) | Neutropenia 72/65 Anemia 54/38 ↓Plt 42/22 | Neutropenia 74.5/71 Anemia 67.3/50.9 ↓Plt 50.9/29.1 | Neutropenia 48.8/48.8 Anemia 48.8/37. 4 ↓Plt 30.9/23. 6 | Neutropenia 32.5/30.8 Anemia 27.4/23.9 ↓Plt 17.1/13.7 | Neutropenia 55/45 Anemia 47/27 ↓Plt 37/16 | Neutropenia 37/34 Anemia 29/16 ↓Plt 23/12 | Neutropenia 40/34 Anemia 44/34 ↓Plt 28/18 |
| Infections, % | 80 (55.2 G3-4) | 74.5 (27.3 G3-4) | 69.9 (39.8 G3-4) | 59.8 (36.8 G3-4) | 62 (16 G3-4) | 41 (5 G3-4) | 59 (25 G3-4) |
| Hypogammaglobulinemia, % | 74.5 | — | 98.6 | — | — | 14 | — |
| CRS, % | 72.1 (0.6 G3) | 87.3 (0 G3) | 56.3 (0 G3) | 45.3 (0.9 G3) | 56 (0 G3) | 57 (2 G3) | 30 (2 G3) |
| ICANS, % | 3 (0 G3-4) | 6.7 (0 G3-4) | 3.4 (0 G3-4) | 5.9 (1.8 G3-4) | 0.03 (0 G3-4) | 0.02 | 0.03 (0 G3-4) |
| Variable . | Teclistamab5,6 . | Elranatamab7 . | Elranatamab8 . | Linvoseltamab10 . | Alnuctamab11,12 . | ABBV-38313,15 . | HPN-217-300114 . |
|---|---|---|---|---|---|---|---|
| Patients, n | 165 | 55 | 123 | 117 | 73 | 124 | 97 |
| Dosing schedule | Weekly/q2w SC | Weekly/q2w SC | Weekly/q2w IV | Weekly/q2w or q4w IV | Weekly/q2-4w IV/SC | Q3w-q4w IV | Weekly/q2w |
| Median prior LOT | 5 | 6 | 5 | 5 | 4 | 5 | 6 |
| ISS III/ ↑↑ PC, % | 12.3/11.2 | 20/— | 15.4/21.1 | 18.8/22.2 | 16/— | 31/— | 38/— |
| HR/EMD, % | 25.7/17 | 29.1/30.9 | 25.2/31.7 | 35.9/13.7 | 26/21 | 18/— | 19/10 |
| TCR, % | 77.6 | 90.9∗ | 100 | 73.5 | 63 | 82 | 78 |
| ORR/≧ CR, % at RP2D | 63/45.5 1500 μg/kg SC | 64/38.2 76 mg SC | 61/35 76 mg SC | 71/30 200 mg IV | 69/43 30 mg SC | 57/28 40-60 mg IV | 63/21 12 mg |
| Median DOR | 21.6 mo | 17.1 mo | 71.5% at 15 mo | — | — | 72.2% at 12 mo† | 20.5 mo |
| Median PFS | 11.3 mo ≦ 3 LOT 18.1 mo | 11.8 mo | 50.9% at 15 mo | 72.7% at 6 mo | 53% at 12 mo | 10.4 mo 57.9% at 12 mo† | — |
| Median OS | 21.9 mo | 21.2 mo | 56.7% at 15 mo | — | — | — | — |
| Hematological AE (any grade/G3-4) | Neutropenia 72/65 Anemia 54/38 ↓Plt 42/22 | Neutropenia 74.5/71 Anemia 67.3/50.9 ↓Plt 50.9/29.1 | Neutropenia 48.8/48.8 Anemia 48.8/37. 4 ↓Plt 30.9/23. 6 | Neutropenia 32.5/30.8 Anemia 27.4/23.9 ↓Plt 17.1/13.7 | Neutropenia 55/45 Anemia 47/27 ↓Plt 37/16 | Neutropenia 37/34 Anemia 29/16 ↓Plt 23/12 | Neutropenia 40/34 Anemia 44/34 ↓Plt 28/18 |
| Infections, % | 80 (55.2 G3-4) | 74.5 (27.3 G3-4) | 69.9 (39.8 G3-4) | 59.8 (36.8 G3-4) | 62 (16 G3-4) | 41 (5 G3-4) | 59 (25 G3-4) |
| Hypogammaglobulinemia, % | 74.5 | — | 98.6 | — | — | 14 | — |
| CRS, % | 72.1 (0.6 G3) | 87.3 (0 G3) | 56.3 (0 G3) | 45.3 (0.9 G3) | 56 (0 G3) | 57 (2 G3) | 30 (2 G3) |
| ICANS, % | 3 (0 G3-4) | 6.7 (0 G3-4) | 3.4 (0 G3-4) | 5.9 (1.8 G3-4) | 0.03 (0 G3-4) | 0.02 | 0.03 (0 G3-4) |
—, Not reported; AE, adverse event; CR, complete response; CRS, cytokine release syndrome; DOR, duration of response; EMD, extramedullary disease; G3, grade 3; HR, high-risk cytogenetics; ICANS, immune effector cell–associated neurotoxicity; ISS, International Staging System; LOT, line of therapy; ↑↑ PC, >50% to 60% bone marrow plasma cells; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; ↓Plt, thrombocytopenia; q2w, every 2 weeks; q3w, every 3 weeks; q4w, every 4 weeks; RP2D, recommended phase 2 dose; SC, subcutaneously; TCR, triple-class refractory.
At 23.6% before anti-BCMA.
Median PFS at ≥ 40-mg dose level.